Advancement in use of silicon pthalocyanine derivatives for cancer treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Porphyrin and Phthalocyanine Chemistry · Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (97)
Show source-provided references
1. 2018
2. Genomic instability and cancer: an introduction10.1093/jmcb/mjq057 ↗
3. Mercadante · 2022
4. The cytoskeleton and cancer10.1007/s10555-008-9166-3 ↗
5. Cooper · 2000
6. Cell cycle control in cancer10.1038/s41580-021-00404-3 ↗
7. The cell cycle and regulation of cancer cell growth10.1111/j.1749-6632.1996.tb16240.x ↗
8. Genetic determinants of cancer metastasis10.1038/nrg2101 ↗
9. Metastasis of cancer: when and how?10.1093/annonc/mdx327 ↗
10. On the origin of cancer metastasis10.1615/CritRevOncog.v18.i1-2.40 ↗
11. A perspective on cancer cell metastasis10.1126/science.1203543 ↗
12. 2020
13. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
14. Cancer statistics for the year 2020: an overview10.1002/ijc.33588 ↗
15. The ever-increasing importance of cancer as a leading cause of premature death worldwide10.1002/cncr.33587 ↗
16. Current cancer epidemiology10.2991/jegh.k.191008.001 ↗
17. Breast cancer: epidemiology and etiology10.1007/s12013-014-0459-6 ↗
18. The epidemiology of prostate cancer
19. Lung cancer epidemiology: contemporary and future challenges worldwide10.21037/atm.2016.03.11 ↗
20. Cyclin-dependent kinase modulators and cancer therapy10.1007/BF03261895 ↗
21. Molecular basis of antifolate resistance10.1007/s10555-007-9049-z ↗
22. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance10.1016/j.drup.2012.07.002 ↗
23. Targeting multidrug resistance in cancer10.1038/nrd1984 ↗
24. Nurgali · 2018 · vol. 9 · 1
25. Mechanisms of cancer drug resistance10.1146/annurev.med.53.082901.103929 ↗
26. Review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance10.2174/156800909788166583 ↗
27. Drug resistance to targeted therapies: Déjà vu all over again10.1016/j.molonc.2014.05.004 ↗
28. Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics10.1016/j.drup.2016.07.001 ↗
29. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer10.1158/0008-5472.CAN-10-1783 ↗
30. Photodynamic therapy for breast cancer in a BALB/c mouse model10.3802/jgo.2012.23.2.115 ↗
31. Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer10.1016/j.pdpdt.2011.08.004 ↗
32. Photoelectric evaluation of dye-sensitized solar cells based on prodigiosin pigment derived from Serratia marcescens 11E10.1016/j.dyepig.2020.108278 ↗
33. Photodynamic therapy in cancer treatment - an update review
34. BODIPY dyes in photodynamic therapy10.1039/C2CS35216H ↗
35. Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy10.1080/10717544.2018.1435751 ↗
36. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy10.1021/acs.chemrev.1c00381 ↗
37. Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)10.1039/C7BM00392G ↗
38. Molecular pathways in cancer response to photodynamic therapy10.1142/S1088424619300064 ↗
39. Phthalocyanines as medicinal photosensitizers: developments in the last five years10.1016/j.ccr.2017.08.003 ↗
40. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy
41. Recent advances in photodynamic therapy for cancer and infectious diseases10.1002/wnan.1560 ↗
42. Photodynamic efficiency: from molecular photochemistry to cell death10.3390/ijms160920523 ↗
43. Targeted photodynamic therapy as potential treatment modality for the eradication of colon cancer and colon cancer stem cells10.1177/1010428317734691 ↗
44. EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer10.1016/j.jconrel.2016.03.014 ↗
45. Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy10.1039/C8OB02902D ↗
46. State of the art in tumor antigen and biomarker discovery10.3390/cancers3022554 ↗
47. Like a bolt from the blue: phthalocyanines in biomedical optics
48. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity10.1186/1471-2407-14-389 ↗
49. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer10.1016/j.molonc.2014.01.006 ↗
50. A nanostructured phthalocyanine/albumin supramolecular assembly for fluorescence turn-on imaging and photodynamic immunotherapy10.1021/acsnano.1c10565 ↗
51. Structure and electrical conduction properties of phthalocyanine thin films10.1016/S0010-8545(96)01238-6 ↗
52. Phthalocyanine-containing polymers10.1039/b000793p ↗
53. Phthalocyanine thio-pyridinium derivatives as antibacterial photosensitizers10.1111/j.1751-1097.2012.01113.x ↗
54. Silicon phthalocyanines: synthesis and resurgent applications10.1039/D0OB02299C ↗
55. Photoinactivation of single and mixed biofilms of Candida albicans and non-albicans Candida species using Photodythazine® [corrected]10.1016/j.pdpdt.2016.11.013 ↗
56. Synthesis and spectroscopic properties of Zn(II) mono-2-(t-butyl)phthalocyanine10.1246/cl.1988.1359 ↗
57. Axial reactivity of soluble silicon(IV) phthalocyanines10.1021/ic000968w ↗
58. Electrochemical and in situ spectroelectrochemical investigations into the redox and aggregation behaviours of phthalocyanines bearing octyl 4-phenyloxyacetate moieties10.1002/(SICI)1099-1409(199801/02)2:1<1::AID-JPP43>3.0.CO;2-L ↗
59. Phthalocyaninosilicon compounds10.1021/ic50002a008 ↗
60. Peripheral and axial substitution of phthalocyanines with solketal groups: synthesis and In vitro evaluation for photodynamic therapy10.1021/jm061136w ↗
61. Syntheses and properties of a series of cationic water soluble phthalocyanines10.1021/jm070781f ↗
62. Phthalocyanines as photosensitizers in the photodynamic therapy of cance10.1111/j.1751-1097.1992.tb08510.x ↗
63. Hexacoordinate bonding and aromaticity in silicon phthalocyanine10.1016/j.theochem.2004.08.043 ↗
64. Russ. The synthesis, characterization, and theoretical analysis of novel Si-substituted silylethyl derivatives of 2-mercaptobenzoxazole and 2-mercaptobenzothiazole
65. Reactivity of penta- and hexacoordinate silicon compounds and their role as reaction intermediates10.1021/cr00020a003 ↗
66. Molecular and electronic structure of penta- and hexacoordinate silicon compounds10.1007/3-540-15811-1_3 ↗
67. Hexacoordinate bonding and aromaticity in silicon phthalocyanine10.1021/jp109278v ↗
68. Novel unsymmetrical silicon(IV) phthalocyanines as highly potent anticancer photosensitizers. Synthesis, characterization, and in vitro photodynamic activities10.1016/j.dyepig.2020.108286 ↗
69. Phthalocyanines: from outstanding electronic properties to emerging applications10.1002/tcr.20139 ↗
70. Optically active porphyrin and phthalocyanine systems10.1021/acs.chemrev.5b00588 ↗
71. Dichloro(phthalocyanino)silicon10.1021/ic50023a036 ↗
72. Peripheral and axial substitution of phthalocyanines with solketal groups: synthesis and in vitro evaluation for photodynamic therapy10.1021/jm061136w ↗
73. Tumor-selective new piperazine-fragmented silicon phthalocyanines initiate cell death in breast cancer cell lines10.1016/j.jphotobiol.2021.112143 ↗
74. Cancer statistics, 2021
75. Synthesis of axially disubstituted silicon phthalocyanines and investigation of photodynamic effects on HCT-116 colorectal cancer cell line10.1016/j.pdpdt.2018.05.009 ↗
76. An epidermal growth factor receptor-targeted and endoplasmic reticulum-localized organic photosensitizer toward photodynamic anticancer therapy10.1016/j.ejmech.2019.111625 ↗
77. Non-aggregated axially disubstituted silicon phthalocyanines: synthesis, DNA cleavage and in vitro cytotoxic/phototoxic anticancer activities against SH-SY5Y cell line10.1016/j.dyepig.2019.107794 ↗
78. Synthesis of axially disubstituted quaternized silicon phthalocyanines as a promising photosensitizer for photodynamic treatment of HCT-116, A549 and SH-SY5Y cancer cell lines10.1039/D0DT00244E ↗
79. A translational study of a silicon phthalocyanine substituted with a histone deacetylase inhibitor for photodynamic therapy10.1021/acsomega.0c03180 ↗
80. Synthesis of axially disubstituted silicon phthalocyanines and investigation of their in vitro cytotoxic/phototoxic anticancer activities10.1142/S1088424620500455 ↗
81. Silicon phthalocyanines axially disubstituted with erlotinib towards small molecular target-based photodynamic therapy10.1002/cmdc.201700384 ↗
82. Glycyrrhetinic acid-modi fi ed silicon phthalocyanine for liver cancer-targeted photodynamic therapy10.1021/acs.biomac.0c01550 ↗
83. Hepatocellular carcinoma
84. Water soluble axially morpholine disubstituted silicon phthalocyanines: synthesis, characterisation, DNA/BSA binding, DNA photocleavage properties
85. Photodynamic therapy effect of morpholinium containing silicon (IV) phthalocyanine on HCT-116 Cells,Photodiagnosis10.1016/j.pdpdt.2020.101975 ↗
86. A novel water soluble axially substituted silicon(IV) phthalocyanine bearing quaternized 4-(4-Pyridinyl)Phenol groups: synthesis, characterization, photophysicochemical properties and BSA/DNA binding behavior10.1016/j.poly.2020.114937 ↗
87. A biotin receptor-targeted silicon(IV) phthalocyanine for in vivo tumor imaging and photodynamic therapy10.1016/j.jphotobiol.2018.09.001 ↗
88. Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates10.1016/j.ejmech.2018.05.039 ↗
89. Axially substituted silicon phthalocyanine payloads for antibody-drug conjugates10.1055/a-1503-6425 ↗
90. The photo-physicochemical properties and in vitro sonophotodynamic therapy activity of di-axially substituted silicon phthalocyanines on PC3 prostate cancer cell line10.1016/j.dyepig.2020.108760 ↗
91. The promise of sonodynamic therapy10.1007/s10555-013-9461-5 ↗
92. Synthesis, DNA interaction, topoisomerase I, II inhibitory and cytotoxic effects of water soluble silicon (IV) phthalocyanine and napthalocyanines bearing 1-acetylpiperazine units10.1016/j.dyepig.2018.08.005 ↗
93. DNA binders in clinical trials and chemotherapy10.1016/j.bmc.2014.05.030 ↗
94. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives10.1016/j.bmcl.2013.03.037 ↗
95. Design, synthesis and biological evaluation of water soluble and non-aggregated silicon phthalocyanines, naphthalocyanines against A549, SNU-398, SK-MEL128, DU-145, BT-20 and HFC cell lines as potential anticancer agents10.1016/j.bioorg.2021.104637 ↗
96. Synthesis of water soluble silicon phthacyanine ,naphthalocyanine bearing pyridine groups and investigation of their DNA interaction , topoisomerase inhibition , cytotoxic effects and cell cycle arrest properties10.1016/j.dyepig.2019.01.044 ↗
97. Phthalocyanines bearing silazane group for colorectal cancer10.1016/j.dyepig.2021.109832 ↗